{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/33873"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/33873","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"Development of Tools to Facilitate Shared Decision-Making in the Treatment Of ANCA-Associated Vasculitis","abstract":"Anti-neutrophil cytoplasmic antibody associated vasculitis (AAV) is a rare, potentially life threatening, multisystem autoimmune disease. Induction therapies with glucocorticoids and drugs such as cyclophosphamide and/or rituximab are able to control active AAV in 95% of individuals. After entering remission, however, individuals require long-term monitoring and treatment to prevent relapse of their disease. Rituximab is the current standard of care medication to maintain disease control. It, and other medications to maintain control of AAV, however, also have side effects including as infection. Individuals with AAV may have goals and priorities around long-term therapy that affect clinical decision-making. There are currently no established methods or tools to synthesize treatment-related information, facilitate shared decision-making, and decide on a preferred individual treatment. In the first chapter, I used data from the largest randomized controlled trial in AAV to date to develop and internally validate a model to quantitatively estimate risk of relapse in individuals with severe AAV. In the second chapter, I completed a systematic review of published values, preferences, and informational needs of individuals with AAV to understand what factors they may consider important in deciding on a particular maintenance treatment strategy. In the third chapter I developed a protocol for the development of an encounter decision aid (EDA) to facilitate shared decision-making for maintenance treatment in AAV. This protocol synthesizes information from the previous chapters and modern methods in EDA development modified for rare diseases to create a pragmatic approach that can be used in other multisystem rheumatic diseases. This thesis thus creates an approach to individualizing care in AAV that can be used both in the clinical settings and in future research to subgroup individuals into lower and higher risk of relapse.","abstract_html":"Anti-neutrophil cytoplasmic antibody associated vasculitis (AAV) is a rare, potentially life threatening, multisystem autoimmune disease. Induction therapies with glucocorticoids and drugs such as cyclophosphamide and/or rituximab are able to control active AAV in 95% of individuals. After entering remission, however, individuals require long-term monitoring and treatment to prevent relapse of their disease. Rituximab is the current standard of care medication to maintain disease control. It, and other medications to maintain control of AAV, however, also have side effects including as infection. Individuals with AAV may have goals and priorities around long-term therapy that affect clinical decision-making. There are currently no established methods or tools to synthesize treatment-related information, facilitate shared decision-making, and decide on a preferred individual treatment. In the first chapter, I used data from the largest randomized controlled trial in AAV to date to develop and internally validate a model to quantitatively estimate risk of relapse in individuals with severe AAV. In the second chapter, I completed a systematic review of published values, preferences, and informational needs of individuals with AAV to understand what factors they may consider important in deciding on a particular maintenance treatment strategy. In the third chapter I developed a protocol for the development of an encounter decision aid (EDA) to facilitate shared decision-making for maintenance treatment in AAV. This protocol synthesizes information from the previous chapters and modern methods in EDA development modified for rare diseases to create a pragmatic approach that can be used in other multisystem rheumatic diseases. This thesis thus creates an approach to individualizing care in AAV that can be used both in the clinical settings and in future research to subgroup individuals into lower and higher risk of relapse.","abstract_has_math":false,"creators":["Junek, Mats"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Clinical Health Sciences (Health Research Methodology)","school":null,"contributors":[],"advisors":["Walsh, Michael"],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-18T19:30:43Z","subjects":[],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/25642"],"render_values":[{"text":"https://doi.org/10.71548/25642","href":"https://doi.org/10.71548/25642","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/11375/33873","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/11375/33873","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F33873","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Walsh, Michael"]},{"key":"dc:contributor.department","label":"Department","values":["Clinical Health Sciences (Health Research Methodology)"]},{"key":"dc:creator","label":"Author","values":["Junek, Mats"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-10-19T14:50:35Z"]},{"key":"dc:date.issued","label":"Date","values":["2026"]},{"key":"dc:type","label":"Dc Type","values":["Dissertation","Thesis"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/11375/33873","https://doi.org/10.71548/25642"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Anti-neutrophil cytoplasmic antibody associated vasculitis (AAV) is a rare, potentially life threatening, multisystem autoimmune disease. Induction therapies with glucocorticoids and drugs such as cyclophosphamide and/or rituximab are able to control active AAV in 95% of individuals. After entering remission, however, individuals require long-term monitoring and treatment to prevent relapse of their disease. Rituximab is the current standard of care medication to maintain disease control. It, and other medications to maintain control of AAV, however, also have side effects including as infection. Individuals with AAV may have goals and priorities around long-term therapy that affect clinical decision-making. There are currently no established methods or tools to synthesize treatment-related information, facilitate shared decision-making, and decide on a preferred individual treatment. In the first chapter, I used data from the largest randomized controlled trial in AAV to date to develop and internally validate a model to quantitatively estimate risk of relapse in individuals with severe AAV. In the second chapter, I completed a systematic review of published values, preferences, and informational needs of individuals with AAV to understand what factors they may consider important in deciding on a particular maintenance treatment strategy. In the third chapter I developed a protocol for the development of an encounter decision aid (EDA) to facilitate shared decision-making for maintenance treatment in AAV. This protocol synthesizes information from the previous chapters and modern methods in EDA development modified for rare diseases to create a pragmatic approach that can be used in other multisystem rheumatic diseases. This thesis thus creates an approach to individualizing care in AAV that can be used both in the clinical settings and in future research to subgroup individuals into lower and higher risk of relapse."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Doctor of Philosophy (PhD)"]},{"key":"dc:title","label":"Title","values":["Development of Tools to Facilitate Shared Decision-Making in the Treatment Of ANCA-Associated Vasculitis"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Walsh, Michael"],"dc:contributor.department":["Clinical Health Sciences (Health Research Methodology)"],"dc:creator":["Junek, Mats"],"dc:date.accessioned":["2026-10-19T14:50:35Z"],"dc:date.issued":["2026"],"dc:description.abstract":["Anti-neutrophil cytoplasmic antibody associated vasculitis (AAV) is a rare, potentially life threatening, multisystem autoimmune disease. Induction therapies with glucocorticoids and drugs such as cyclophosphamide and/or rituximab are able to control active AAV in 95% of individuals. After entering remission, however, individuals require long-term monitoring and treatment to prevent relapse of their disease. Rituximab is the current standard of care medication to maintain disease control. It, and other medications to maintain control of AAV, however, also have side effects including as infection. Individuals with AAV may have goals and priorities around long-term therapy that affect clinical decision-making. There are currently no established methods or tools to synthesize treatment-related information, facilitate shared decision-making, and decide on a preferred individual treatment. In the first chapter, I used data from the largest randomized controlled trial in AAV to date to develop and internally validate a model to quantitatively estimate risk of relapse in individuals with severe AAV. In the second chapter, I completed a systematic review of published values, preferences, and informational needs of individuals with AAV to understand what factors they may consider important in deciding on a particular maintenance treatment strategy. In the third chapter I developed a protocol for the development of an encounter decision aid (EDA) to facilitate shared decision-making for maintenance treatment in AAV. This protocol synthesizes information from the previous chapters and modern methods in EDA development modified for rare diseases to create a pragmatic approach that can be used in other multisystem rheumatic diseases. This thesis thus creates an approach to individualizing care in AAV that can be used both in the clinical settings and in future research to subgroup individuals into lower and higher risk of relapse."],"dc:description.degree":["Doctor of Philosophy (PhD)"],"dc:identifier.uri":["https://hdl.handle.net/11375/33873","https://doi.org/10.71548/25642"],"dc:language.iso":["en"],"dc:title":["Development of Tools to Facilitate Shared Decision-Making in the Treatment Of ANCA-Associated Vasculitis"],"dc:type":["Dissertation","Thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:30:43Z"}